PERTZYE is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
-
Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PERTZYE exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
-
To avoid irritation of oral mucosa, do not chew PERTZYE or retain in the mouth.
-
Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or renal impairment.
-
Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
-
There is theoretical risk of viral transmission with all pancreatic enzyme products including PERTZYE.
The most common adverse reactions (≥ 10%) are: diarrhea, dyspepsia, and cough.
copyright 2017, Digestive Care, Inc.,
design by Matthew Kramer Art & Design, all rights reserved